Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 3/20 | 0.46 |
| ▸ | LITAF | Q99732 | 3/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 3/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | ABL2 | P42684 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13007640 | 1.00 | TNF (0.46) | TNFLITAFPIK3CAGPR119HSD11B1 | |
| SCHEMBL3764149 | 0.94 | GPR119 (0.44) | TNFLITAFPIK3CAGPR119NR3C1 | |
| SCHEMBL3673403 | 0.84 | HSD11B1 (0.37) | HSD11B1 | |
| SCHEMBL3769226 | 0.84 | HSD11B1 (0.37) | HSD11B1 | |
| SCHEMBL3775193 | 0.80 | CHRNA7 (0.36) | TNFLITAFHSD11B1 | |
| SCHEMBL2636985 | 0.79 | HSD11B1 (0.62) | TNFLITAFPIK3CAHSD11B1SRC | |
| SCHEMBL2636984 | 0.79 | HSD11B1 (0.62) | TNFLITAFPIK3CAHSD11B1SRC | |
| SCHEMBL2636722 | 0.77 | HSD11B1 (0.59) | TNFLITAFPIK3CAHSD11B1USP30 | |
| SCHEMBL2636724 | 0.77 | HSD11B1 (0.59) | TNFLITAFPIK3CAHSD11B1USP30 | |
| SCHEMBL16763620 | 0.73 | FPR2 (0.49) | TNFLITAFPIK3CAGPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851484-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851484-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | TNNC1, TNNI3, TNNT2 | TNF 752/4885LITAF 411/4885PIK3CA 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.